PD-0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance.

These findings suggest that PD-0332991 could reverse the acquired resistance of cisplatin in lung cancer cells and provide a novel treatment strategy for lung cancer patients with cisplatin resistance.